Single-operator Digital Cholangioscopy for the Diagnosis of Malignant and Benign Biliary Strictures

August 20, 2023 updated by: Raymond Shing Yan Tang, Chinese University of Hong Kong

Evaluation of the Utility of Single-operator Digital Cholangioscopy During Endoscopic Retrograde Cholangiopancreatography in the Diagnosis of Malignant and Benign Biliary Strictures

Differentiation between malignant and benign biliary strictures can be challenging. Accurate differentiation of malignant biliary strictures from benign ones is crucial to guide management decisions.

While conventional tissue acquisition techniques such as brush cytology or intraductal biopsy of the biliary stricture is often performed during ERCP for tissue diagnosis, their sensitivities are suboptimal. The average sensitivities for brush cytology and intraductal biopsy were reported to be ~ 59% and ~ 63% respectively.

When the cause of a biliary stricture remains unclear despite conventional ERCP techniques for diagnosis, cholangioscopy is often performed during ERCP to clarify the diagnosis. This allows an endoscopist to obtain a visual impression (VI) and to perform targeted biopsy under direct visualization of the biliary stricture.

Recently, a digital SOC system (SpyGlass Digital System (SpyGlass DS), Boston Scientific, USA) has become available and has the potential to further improve the diagnosis of malignant and benign biliary strictures. The utility of this digital SOC in the evaluation of biliary strictures has not been well studied. We propose this study to evaluate the utility of the digital SOC during ERCP in the diagnosis of malignant and benign biliary strictures.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Differentiation between malignant and benign biliary strictures can be challenging. Accurate differentiation of malignant biliary strictures from benign ones is crucial to guide management decisions. While a mass lesion involving the bile duct may be observed on imaging such as ultrasound (USG), computed tomography (CT), or magnetic resonance imaging (MRI) in patient presenting with obstructive jaundice, early malignancy of the bile duct may often present with a ductal stricture without an obvious mass on imaging. Diagnosis of early stage malignancy of the bile duct is desirable since the lesion may be amenable to surgical resection of curative intent.

Endoscopic retrograde cholangiopancreatography (ERCP) is an important diagnostic and therapeutic endoscopic technique in patients with obstructive jaundice and a suspected biliary stricture. While conventional tissue acquisition techniques such as brush cytology or intraductal biopsy of the biliary stricture is often performed during ERCP for tissue diagnosis, their sensitivities are suboptimal. The average sensitivities for brush cytology and intraductal biopsy were reported to be ~ 59% and ~ 63% respectively.

When the cause of a biliary stricture remains unclear despite conventional ERCP techniques for diagnosis, cholangioscopy is often performed during ERCP to clarify the diagnosis. Cholangioscopy performed during ERCP involves passing a small scope (~ 10 French in size) through the working channel of the ERCP duodenoscope for direct visualization of the bile duct mucosa. This allows an endoscopist to obtain a visual impression (VI) and to perform targeted biopsy under direct visualization of the biliary stricture. The VI of a malignant biliary stricture is often characterized by the presence of intraductal abnormal tissue growth, and dilated, irregular, tortuous tumor vessels. During standard ERCP, cholangioscopy can be performed using a 2-operator "mother-baby" system, or a single-operator system. While the 2-operator "mother-baby" cholangioscopy technique can provide good image quality of the biliary stricture during ERCP, its use has been limited due to the cumbersome nature of the procedure requiring 2 endoscopists and the relative fragility of the video cholangioscope. Single-operator cholangioscopy (SOC) system, such as the SpyGlass Direct Visualization System, on the other hand allows a single operator to perform cholangioscopy during ERCP. In a recent meta-analysis of the studies using the optical fiber based SOC in the evaluation of indeterminate biliary strictures, the combined sensitivity and specificity of VI were 90% and 87% respectively, and the combined sensitivity and specificity of cholangioscopy directed biopsy were 69% and 98% respectively. The overall incidence of procedure-related adverse event (eg, infection, perforation, pancreatitis, etc) was reported to be 7.5% for diagnostic SOC during ERCP.

Despite the promising results of VI using the optical fiber based SOC from prior studies, the actual image quality in daily clinical practice is frequently regarded as fair only due to the use of a small optical fiber for imaging, and gradual loss of resolution over time from optical fiber damage. A SOC with better image quality is needed for better endoscopic diagnosis of a biliary stricture.

Recently, a digital SOC system (SpyGlass Digital System (SpyGlass DS), Boston Scientific, USA) has become available and has the potential to further improve the diagnosis of malignant and benign biliary strictures. The utility of this digital SOC in the evaluation of biliary strictures has not been well studied. We propose this study to evaluate the utility of the digital SOC during ERCP in the diagnosis of malignant and benign biliary strictures.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • New Territories
      • Sha Tin, New Territories, Hong Kong
        • Recruiting
        • Prince of Wales Hospital, The Chinese University of Hong Kong
        • Contact:
        • Principal Investigator:
          • Raymond S Tang, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age ≥ 18 years
  • Patients presenting with obstructive jaundice with clinical suspicion for a biliary stricture based on imaging findings or during ERCP
  • Written informed consent available

Exclusion Criteria:

  • Contraindications for endoscopy due to comorbidities
  • Unable to provide written informed consent
  • Patients with clinical evidence of ongoing cholangitis precluding a safe cholangioscopy procedure
  • Pregnant patients
  • Moribund patients from terminal illnesses

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SpyGlass DS Cholangioscopy
ERCP with cholangiogram will be performed to assess the common bile duct (CBD) and intrahepatic ducts (IHD) for presence of a stricture. Once a biliary stricture is confirmed on cholangiogram during ERCP, SpyGlass DS Cholangioscopy would be performed. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy. Endoscopic stenting will be performed in standard fashion for biliary drainage to relieve the obstructive jaundice.
SpyGlass DS Cholangioscopy includes a 10 French diameter single use digital cholangioscope and a light source with the digital sensor. During ERCP with cholangioscopic exam, the cholangioscope would be first inserted through the working channel of the duodenoscope and subsequently passed into the bile duct for direct visualization of the bile duct mucosa. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
sensitivity, specificity, and accuracy of the digital SOC during ERCP in the diagnosis of malignant and benign biliary strictures.
Time Frame: Till a diagnosis of a malignant stricture is made, or follow up period of at least 6 months for presumed benign stricture
To assess the sensitivity, specificity, and accuracy of digital SOC in the diagnosis of biliary strictures
Till a diagnosis of a malignant stricture is made, or follow up period of at least 6 months for presumed benign stricture

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Raymond S Tang, MD, Prince of Wales Hospital, The Chinese University of Hong Kong

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 15, 2015

Primary Completion (Estimated)

December 31, 2024

Study Completion (Estimated)

December 31, 2024

Study Registration Dates

First Submitted

October 2, 2017

First Submitted That Met QC Criteria

October 5, 2017

First Posted (Actual)

October 11, 2017

Study Record Updates

Last Update Posted (Actual)

August 22, 2023

Last Update Submitted That Met QC Criteria

August 20, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Biliary Stricture

Clinical Trials on SpyGlass DS Cholangioscopy

3
Subscribe